Gracell Biotechnologies Inc reports results for the quarter ended in June - Earnings Summary

Gracell Biotechnologies

15/08/2022 14:31

* Gracell Biotechnologies Inc  GRCL.OQ  reported a quarterly
adjusted loss of 30 cents​​ per share for the quarter ended in
June. The mean expectation of five analysts for the quarter was
for a loss of 7 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Gracell Biotechnologies Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Gracell Biotechnologies Inc shares had fallen by 38.5%
this
quarter and lost 44.0% so far this year.
    * The company reported a quarterly loss of $21.84 million.
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $20.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data August 15
at 01:31 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2022      -0.07          -0.30          Missed
 Mar. 31 2022      -0.21          -0.35          Missed
 Dec. 31 2021      -0.33          -0.30          Beat
 Sep. 30 2021      -0.12          -0.30          Missed